Clinical Trial Update: Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma [Phase 2]

View source ↗

Summary

This update notes the termination of the Phase 2 trial of MK-2206 in relapsed or refractory diffuse large B-cell lymphoma. No efficacy results are provided in t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: Centre Leon Berard | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: TERMINATED